Risk Management & Treatment

Screening for pancreatic cancer

This section covers the following topics:

  • Types of pancreatic cancer screening
  • Pancreatic cancer screening guidelines for high risk people

Experts do not recommend screening healthy people at average risk for pancreatic cancer. In people at high for pancreatic cancer, screening is only recommended for certain people. 


Types of pancreatic cancer screening

  • Contrast-enhanced magnetic resonance cholangiopancreatography (MRCP) is a special type of MRI imaging that looks closely at the pancreas, liver, gallbladder, bile duct and pancreatic duct to find abnormalities such as cancer. People undergoing MRCP must fast for four hours before the procedure. An injection of contrast agent—called gadolinium—is given before the test in order to help radiologists to find abnormalities more easily.
  • Endoscopic ultrasound (EUS) involves passing a tiny scope with an attached ultrasound probe down the esophagus to the stomach. This allows doctors to look closely at the pancreas. EUS is performed as an outpatient procedure under anesthesia. 


Screening for people with inherited mutations

NCCN recommends that people undergoing pancreatic screening have the procedure at an experienced facility, and ideally as part of a research study. Before undergoing screening, people should have a conversation with their doctor about the potential benefits, risks, costs and limitations of screening.

NCCN recommends that people with inherited mutations in the following genes (with or without a family history of cancer) "consider pancreatic cancer screening" with MRCP or EUS:

  • STK11: (Peutz-Jeghers syndrome): Consider pancreatic cancer screening by MRCP or EUS every 1-2 years beginning at age 30-35 or 10 years younger than the earliest pancreatic cancer in the family.
  • CDKN2A: Consider pancreatic cancer screening beginning at age 40 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family.

NCCN guidelines recommend that people with an inherited mutation in one of the following genes and a family history of cancer "consider pancreatic cancer screening" with MRCP or EUS beginning at age 50 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family:

NCCN does not currently recommend pancreatic cancer screening for people with the above mutations who do not have a family history of cancer. 

clinical-trials

The following screening and prevention studies are open to people at high risk for pancreatic cancer.